Batimastat

TargetMol
Product Code: TAR-T6011
Supplier: TargetMol
CodeSizePrice
TAR-T6011-1mg1mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6011-5mg5mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6011-1mL1 mL * 10 mM (in DMSO)£166.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6011-10mg10mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6011-25mg25mg£360.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6011-50mg50mg£532.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6011-100mg100mg£732.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Batimastat (BB-94) is an effective, broad-spectrum matrix metalloprotease (MMP) inhibitor. Batimastat induces extracellular matrix degradation and inhibits angiogenesis, tumor growth and invasion, and metastasis.
CAS:
130370-60-4
Formula:
C23H31N3O4S2
Molecular Weight:
477.64
Pathway:
Proteases/Proteasome
Purity:
0.995
SMILES:
CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO
Target:
MMP

References

Liu Y, Wei H, Tang J, et al. Dysfunction of pulmonary epithelial tight junction induced by silicon dioxide nanoparticles via the ROS/ERK pathway and protein degradation[J]. Chemosphere. 2020, 255: 126954. Liu Y, Wei H, Tang J, et al. Dysfunction of pulmonary epithelial tight junction induced by silicon dioxide nanoparticles via the ROS/ERK pathway and protein degradation. Chemosphere. 2020, 255: 126954. Botos I, et al. PNAS, 1996, 93(7), 2749-2754. Taraboletti G, et al. J Natl Cancer Inst, 1995, 87(4), 293-298. Wang X, et al. Cancer Res, 1994, 54(17), 4726-4728. Chirivi RG, et al. Int J Cancer, 1994, 58(3), 460-464.